SEER cancer statistics. 2020. Available from: https://seer.cancer.gov/statfacts/html/prost.html. Accessed 31 Jan 2024.

Thurin NH, Rouyer M, Gross-Goupil M, Rebillard X, Soulié M, Haaser T, et al. Epidemiology of metastatic castration-resistant prostate cancer: a first estimate of incidence and prevalence using the French nationwide healthcare database. Cancer Epidemiol. 2020;69:1–6.

Article  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Srinivasarao M, Galliford CV, Low PS. Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nat Rev Drug Discov. 2015;14:203–19.

Kratochwil C, Giesel FL, Stefanova M, Benesova M, Bronzel M, Afshar-Oromieh A, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-Labeled PSMA-617. J Nucl Med. 2016;57:1170–6.

Article  CAS  PubMed  Google Scholar 

Afshar-Oromieh A, Babich JW, Kratochwil C, Giesel FL, Eisenhut M, Haberkorn U, et al. The rise of PSMA ligands for diagnosis and therapy of prostate cancer. J Nucl Med. 2016;57:79S-89S.

Article  CAS  PubMed  Google Scholar 

Silberstein JL, Pal SK, Lewis B, Sartor O. Current clinical challenges in prostate cancer. Transl Androl Urol. 2013;2:122–36.

Kiess AP, Banerjee SR, Mease RC, Rowe SP, Rao A, Foss CA, et al. Prostate-specific membrane antigen as a target for cancer imaging and therapy. Q J Nucl Med Mol Imaging. 2015;59:241–68.

Hupe MC, Philippi C, Roth D, Kümpers C, Ribbat-Idel J, Becker F, et al. Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis. Front Oncol. 2018;8:1–7.

Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, et al. 68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. Eur J Nucl Med Mol Imaging. 2019;46:31–9.

Article  CAS  PubMed  Google Scholar 

Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091–103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heynickx N, Herrmann K, Vermeulen K, Baatout S, Aerts A. The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: a review of the lessons learnt so far. Nucl Med Biol. 2021;98–99:30–9.

Mahajan S, Grewal RK, Friedman KP, Schöder H, Pandit-Taskar N. Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: current concepts in imaging and management. Transl Oncol. 2022;21:1–8.

Article  Google Scholar 

Lucaroni L, Georgiev T, Prodi E, Puglioli S, Pellegrino C, Favalli N, et al. Cross-reactivity to glutamate carboxypeptidase III causes undesired salivary gland and kidney uptake of PSMA-targeted small-molecule radionuclide therapeutics. Eur J Nucl Med Mol Imaging. 2023;50:957–61.

Article  CAS  PubMed  Google Scholar 

Lückerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R, et al. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Res. 2018;8:1–9.

PSMA I&T + Rad223 combo. https://clinicaltrials.gov/study/NCT05383079. Accessed 6 Jan 2024.

Pretto F, Elia G, Castioni N, Neri D. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy. Cancer Immunol Immunother. 2014;63:901–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Millul J, Bassi G, Mock J, Elsayed A, Pellegrino C, Zana A, et al. An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications. PNAS. 2021;118:1–10.

Article  Google Scholar 

Cazzamalli S, Ziffels B, Widmayer F, Murer P, Pellegrini G, Pretto F, et al. Enhanced therapeutic activity of non-internalizing small-molecule-drug conjugates targeting carbonic anhydrase IX in combination with targeted interleukin-2. Clin Cancer Res. 2018;24:3656–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zegers CML, Rekers NH, Quaden DHF, Lieuwes NG, Yaromina A, Germeraad WTV, et al. Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects. Clin Cancer Res. 2015;21:1151–60.

Article  CAS  PubMed  Google Scholar 

Galbiati A, Dorten P, Gilardoni E, Gierse F, Bocci M, Zana A, et al. Tumor-targeted interleukin 2 boosts the anticancer activity of FAP-directed radioligand therapeutics. J Nucl Med. 2023;64:1934–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Satapathy S, Mittal BR, Sood A, Das CK, Mavuduru RS, Goyal S, et al. [177Lu]Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: final survival analysis of a phase 2 randomized, controlled trial. J Nucl Med. 2023;64:1726–9.

Article  CAS  PubMed  Google Scholar 

Heck MM, Tauber R, Schwaiger S, Retz M, D’Alessandria C, Maurer T, et al. Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer(Figure presented.). Eur Urol. 2019;75:920–6.

Article  CAS  PubMed  Google Scholar